OsteoGen™ bone grafting materials incorporate Bioactive Crystal Technology (BCT), a proprietary system based on non-sintered, biomimetic calcium phosphate crystals intended to support regenerative bone growth. According to the company, the technology is designed to provide a favorable environment for regeneration by using a composition similar to natural bone.
Bioactive Crystal Technology refers to non-sintered calcium phosphate crystals used in all OsteoGen bone grafting materials. Because the crystals are not exposed to high-heat sintering, they retain bioactive properties and participate in the healing process by releasing calcium ions that support osteoblastic differentiation and mineralized matrix deposition. According to the company, rather than functioning only as a scaffold, the material contributes biochemical components for hard tissue regeneration, creating an environment that promotes cellular activity and bone formation. The company states that the resulting graft material is biocompatible, osteoconductive, and bioactive.
Sintering, a high-heat manufacturing process used in many ceramic graft materials, fuses particles into dense structures. According to the company, this process alters the biological behavior of the material. The company states that sintered grafts often remain visible on radiographs indefinitely, which may complicate assessment of bone regeneration, and that dense materials can become encapsulated with connective tissue instead of being fully resorbed.
In contrast, the company reports that its non-sintered BCT graft is radiolucent at placement and gradually becomes radiopaque as it remodels into natural bone, typically within three to five months. According to the company, this radiographic progression parallels natural bone density changes and provides clinicians with a visual indicator of healing and timing for implant placement.
“Bioactive Crystal Technology gives clinicians the best of both worlds: a graft material grounded in solid science that's also practical to use. It remodels like natural bone, and we can see that healing on a radiograph. That's the kind of predictability we need, and we get that from OsteoGen,” states Charles D. Schlesinger, vice ppresident of clinical development, Impladent Ltd.
The company cites independent research published in the Journal of Periodontology. In the study by Jones et al., OsteoGen® Plug achieved 94.4% porosity, which the authors reported created a scaffold environment for vascular infiltration and new bone formation. The study also reported osteoblast proliferation up to six times greater than xenograft and allograft materials. Live cell imaging confirmed greater osteoblast activity across multiple time periods, while the xenograft material was unable to sustain cellular activity.
OsteoGen bone grafting materials are available in Plug, Strip, and Block forms and combine BCT with Type I collagen. According to the company, the OsteoGen Plug eliminates the need for a separate membrane in routine socket preservation cases, which can reduce procedure time and simplify surgical workflow without compromising clinical results.
OsteoGen bone grafting materials are developed by Impladent Ltd. and are designed to support resorbable bone grafting procedures using non-sintered calcium phosphate crystals combined with Type I collagen. More information is available at www.osteogen.com.
